What are the available phosphate binders and their typical dosing regimens?

Available Phosphate Binders

Phosphate binders fall into three main categories: calcium-based, non-calcium-based, and aluminum-based agents, with the choice depending on calcium balance, vascular calcification risk, and cost considerations.

Calcium-Based Phosphate Binders

These are the most commonly used first-line agents due to their efficacy and low cost 1:

• Calcium carbonate: Typical dosing 1-3 grams per meal (provides ~400 mg elemental calcium per gram)
• Calcium acetate: Typical dosing 1-2 grams per meal (provides ~250 mg elemental calcium per gram)

Critical limitation: Total elemental calcium intake from diet and binders should not exceed 2,000 mg/day 1. Studies demonstrate that calcium loads exceeding 1,500 mg/day from binders are associated with progressive vascular and coronary artery calcification 1. When calcium-based binders exceed 2,000 mg total elemental calcium content, you must switch to or add a non-calcium binder 1.

Non-Calcium-Based Phosphate Binders

These are preferred when hypercalcemia exists, calcium load is excessive, or severe vascular calcification is present 1:

• Sevelamer hydrochloride/carbonate: Starting dose 800-1600 mg three times daily with meals; titrate by 400-800 mg per meal every 2 weeks. Has additional benefit of lowering LDL cholesterol 1

• Lanthanum carbonate: Typical dosing 500-1000 mg three times daily with meals 2, 3, 4

• Oxylanthanum carbonate: Novel nanoparticle formulation with the highest phosphate-binding capacity per volume, requiring the lowest daily medication volume 5

• Sucroferric oxyhydroxide: Iron-based binder that provides concurrent iron supplementation 6

• Ferric citrate: Iron-based binder, typical dosing 1-2 grams three times daily with meals; also treats iron deficiency 6

• Magnesium salts (magnesium carbonate/hydroxide): Use with caution due to risk of hypermagnesemia, particularly in patients with residual renal function 2, 3

Aluminum-Based Phosphate Binders

• Aluminum hydroxide/carbonate: Reserved ONLY for short-term use (≤4 weeks) in patients with severe hyperphosphatemia (>7.0 mg/dL) who have failed other agents 1, 4

Critical warning: Never use aluminum binders long-term due to neurotoxicity and osteomalacia risk. Never combine with calcium citrate, as citrate increases aluminum absorption and can precipitate acute toxicity 1.

Dosing Strategy

All phosphate binders must be taken 10-15 minutes before or during meals to maximize phosphate binding 1. The daily dosing frequency with phosphate binders typically increases to 6-7 times per day, compared to 4 times per day without binders 7.

Clinical Algorithm for Selection

1. Start with calcium-based binders (calcium acetate or carbonate) if serum calcium is normal and no severe vascular calcification exists
2. Switch to or add non-calcium binders when:
   • Elemental calcium intake approaches 1,500-2,000 mg/day from binders
   • Hypercalcemia develops (corrected calcium >10.2 mg/dL)
   • PTH is suppressed (low-turnover bone disease)
   • Severe vascular calcification is present 1
3. Consider iron-based binders (ferric citrate or sucroferric oxyhydroxide) when concurrent iron deficiency exists 6
4. Reserve aluminum binders only for refractory hyperphosphatemia >7.0 mg/dL for maximum 4 weeks 1

Key Caveat for CKD Stages 3-4

The 2017 KDIGO guidelines recommend treating only progressive or persistent hyperphosphatemia in non-dialysis CKD patients, not preventing it 8. Evidence for safety and efficacy of phosphate binders in CKD G3a-G4 is lacking, and normophosphatemia alone is not an indication to start treatment 8.